Chairman Seo Jeong-jin, who turned Celltrion into a large bio company with a market cap of 48 trillion won, will resign from the chairmanship today at the age of 63.
Until the new chairman of the board of directors is elected at the general shareholders’ meeting in March next year, he retains his official title, but in business terms, he will serve as chairman only until today.
–
On the 31st, an official from Celltrion said, “Chairman Seo plans to start a startup in the field of ubiquitous healthcare (remote treatment) after retirement.”
Chairman Seo will fulfill his role as chairman until March, but he will not be raised to an official award in the future.
Chairman Seo, who has pledged to succeed in the development of a novel coronavirus infection (Corona 19) treatment, has been self-developed by the Ministry of Food and Drug Safety,’Recyronaju’ (ingredient name legdanvimab, code name CT-P59). By applying for an item permit, he keeps his last promise and retires.
Chairman Seo turned Celltrion into a large bio company with consolidated sales of 1.12.85 billion won and operating profit of 388.1 billion won at the end of last year.
Celltrion has a market capitalization of 48,46.4 billion won as of the day.
In September 2008, it acquired nearly 50 times its size in 12 years after acquiring Oalchem and listing by way.
/yunhap news
–
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution
–
